Sexually transmitted diseases · 2026
Trends in Triple-Site Testing for Chlamydia and Gonorrhea in New York City: A Cross-Sectional Study Using Health Information Exchange Data.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tucker Emma, Reyes Nieva Harry, Castor Delivette, Yin Michael T, Gordon Peter, Elhadad Noémie, Zucker Jason
Аннотация
BACKGROUND: Sexually transmitted infections pose a threat to public health and continue to rise in New York City despite reductions in other parts of the United States. Chlamydia and gonorrhea can infect multiple anatomic sites, including the urogenital tract, pharynx, and rectum. Guidelines recommend multisite testing for select populations, yet multisite testing is not routinely performed, limiting our understanding of trends in positivity and missed infections.
METHODS: We conducted a retrospective cross-sectional study of patients who underwent triple-site testing for chlamydia and gonorrhea in New York City between January 2018 and June 2023 using data from Healthix, the largest public health information exchange in the country. We examined rates of triple-site testing, the prevalence of positivity at any anatomic site, and the proportion of extragenital-only positivity. We fit logistic regression models using generalized estimating equations to identify predictors of triple-site testing as well as overall and extragenital-only positivity.
RESULTS: We identified 11,405 individuals who received triple-site testing during the study period, representing 28,565 triple-site tests, 2742 chlamydia cases, and 2702 gonorrhea cases. The rectum was the most common site of infection for both sexually transmitted infections. Overall, 82% of chlamydia infections (82% in men and 77% in women) and 86% of gonorrhea infections (86% in men and 87% in women) would have been missed with urogenital-only testing.
CONCLUSIONS: In this cross-sectional study of health information exchange data, we examined citywide testing and found that, among patients undergoing triple-site testing, the majority of chlamydia and gonorrhea cases would have been missed through urogenital-only testing.
METHODS: We conducted a retrospective cross-sectional study of patients who underwent triple-site testing for chlamydia and gonorrhea in New York City between January 2018 and June 2023 using data from Healthix, the largest public health information exchange in the country. We examined rates of triple-site testing, the prevalence of positivity at any anatomic site, and the proportion of extragenital-only positivity. We fit logistic regression models using generalized estimating equations to identify predictors of triple-site testing as well as overall and extragenital-only positivity.
RESULTS: We identified 11,405 individuals who received triple-site testing during the study period, representing 28,565 triple-site tests, 2742 chlamydia cases, and 2702 gonorrhea cases. The rectum was the most common site of infection for both sexually transmitted infections. Overall, 82% of chlamydia infections (82% in men and 77% in women) and 86% of gonorrhea infections (86% in men and 87% in women) would have been missed with urogenital-only testing.
CONCLUSIONS: In this cross-sectional study of health information exchange data, we examined citywide testing and found that, among patients undergoing triple-site testing, the majority of chlamydia and gonorrhea cases would have been missed through urogenital-only testing.